Log in to search using one of your social media accounts:

 

BRAF and MAP2K1 Genes Mutation in Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia
Splenic marginal zone lymphoma (SMZL), a specific type of small B-cell lymphoma. Hairy cell leukemia (HCL) has characteristics to distinguish it from other B-cell lymphomas. Sequencing revealed that mutation in BRAF gene detected in 100% of patients HCL and demonstrate constitutive activation of RAF-MEK-ERK-cascade. These findings make a significant contribution to the diagnosis of issues and allow distinguishing HCL from similar B-cell lymphomas, such as SMZL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Hunan Julhakyan, Igor Yakutik, Lyubov Al-Radi, Bella Biderman, Tatyana Moiseeva, Andrey Sudarikov, Valeriy Savchenko Source Type: research

Single Center Experience in Diagnosis of Hepatosplenic T-cell Lymphoma
Hepatosplenic T-cell lymphoma (HSTL) is a rare form of non-Hodgkins lymphoma with involvement of the liver, spleen and bone marrow. Diagnosis and treatment of HSTL are still difficult. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Natalya Chernova, Hunan Julhakyan, Yulia Vinogradova, Yulia Sidorova, Marina Sinitsyna, Alla Kovrigina, Evgeniy Zvonkov, Elena Parovichnikova, Valeriy Savchenko Source Type: research

Treatment of Pediatric B-cell Non-Hodgkin Lymphoma in Croatia
The feasibility of treating children in Croatia with B-cell non-Hodgkin lymphoma (B-NHL) according to very intensive BFM NHL protocols has not been investigated. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jelena Roganovic, Ernest Bilic, Ljubica Rajic, Ranka Femenic Source Type: research

Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study
Although patients with relapsed/refractory DLBCL have heterogeneous outcomes to subsequent therapy, patients with chemorefractory disease (r-DLBCL) have a worse prognosis. SCHOLAR-1 is a patient-level meta-analysis designed to assess outcomes in r-DLBCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Crump, Sattva Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Mohamed Ahmed, Brian Link, Annette Hay, James Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew Maurer, Lynn Navale, Jeffrey Wiezorek, William Go, Christian Gisselbrecht Source Type: research

Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Outcomes in chemorefractory DLBCL are homogeneous and poor (ORR of approximately 26%, median overall survival of 6-7 months) and there is significant unmet need for effective therapies in this patient population. A National Cancer Institute (NCI) study using anti-CD19 CAR T cells with CD28 and CD3 ζ signaling domains showed durable remissions in patients with relapsed/refractory advanced B cell malignancies. KTE-C19 uses the same anti-CD19 construct as the NCI, manufactured using a streamlined 6- to 8-day process. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sattva Neelapu, Frederick Locke, Nancy Bartlett, Tanya Siddiqi, Julio Chavez, Chitra Hosing, Amanda Cashen, Lihua Budde, Adrian Bot, John Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Go Source Type: research

The Genetics of Nodal Marginal Zone Lymphoma
Nodal marginal zone lymphoma (NMZL) is a rare indolent B-cell tumor that is distinguished from splenic marginal zone lymphoma (SMZL) by the different pattern of dissemination. NMZL still lacks distinct markers and remains orphan of specific cancer gene lesions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Valeria Spina, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano Cascione, Alessio Bruscaggin, Elisa Spaccarotella, Antony Holmes, Luca Arcaini, Marco Lucioni, Fabrizio Tabb ò, Sakellarios Zairis, Fary Diop, Michaela Cerri, Sabina Chiaretti, Robert Source Type: research

Enteroviral Infection in Patients Treated with Rituximab for Non Hodgkin Lymphoma: a Case Series and Review of the Literature
The chimeric anti-CD20 monoclonal antibody rituximab is widely used for the treatment of B-cell lymphoproliferative disorders as well as for autoimmune diseases. Rituximab induces depletion of the peripheral B cell pool, leading to hypoglobulinemia which results in decreased antibody response to infections. Enteroviral infection can cause life-threatening meningoencephalitis and other systemic chronic syndromes in immune deficient patients (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sigal Grisariu, Pia Raanani, Ora Paltiel, Oren Pasvolsky, Iuliana Vaxman, Moshe Gatt, Shlomo Elias, Batia Avni, Ariella Arad Source Type: research

The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL)
Aberrant changes in microRNAs (miRNAs), contribute to lymphomagenesis and represent potential therapeutic targets. OTX015 (MK-8628) has demonstrated preclinical and clinical activity in haematological tumours. To better understand the mechanism of action of OTX015 we studied its effects on miRNAs in lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Afua Mensah, Luciano Cascione, Eugenio Gaudio, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Riccardo Bomben, Valter Gattei, Anastasios Stathis, Emanuele Zucca, Ivo Kwee, Francesco Bertoni Source Type: research

Human V δ1+ γδ Peripheral T-Cell Lymphoma/Leukemia are Derived from Natural Killer T (NKT) Cells and Might be Treated with Blocking Anti-CD1d Antibody
Peripheral T-cell lymphomas (PTCL) are a heterogeneous entity of neoplasms with poor prognosis, lack of effective therapies, and a largely unknown pathophysiology. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Emmanuel Bachy, Mirjam Urb, Shilpi Chandra, R émy Robinot, Gabriel Bricard, Simon de Bernard, Alexandra Traverse-Glehen, Sophie Gazzo, Olivier Blond, Archana Khurana, Lucile Baseggio, Tayla Heavican, Martine Ffrench, Giuliano Crispatzu, Paul Mondière, A Source Type: research

Survival Impact of Serum Albumin (SA) in Patients with Acquired Immunodeficiency Syndrome (AIDS) Related Non-Hodgkin's Lymphomas
Despite effective combination antiretroviral therapy for HIV, there is still increased incidence of Acquired Immunodeficiency Syndrome (AIDS) related Non-Hodgkin lymphomas (NHLs). AIDS related NHLs represent a challenge for the practicing oncologist. Prognostic factors have been shown to be useful to risk stratify the disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Joseph Clara, Samir Dalia, Bijal Shah, Celeste Bello, Paul Chervenick, Luis Miguel Juarez Salcedo, Mohamed Kharfan-Dabaja, Lubomir Sokol, Eduardo Sotomayor, Julio Chavez Source Type: research

Long-Term Follow-Up of Primary Intestinal Aggressive Lymphomas Treated with mNHL-BFM-90
The primary intestinal aggressive lymphomas (PIAL) account about 70% of all intestinal lymphomas. Among them, diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) is the most frequent. R-CHOP chemotherapy can induce favorable results for localized-stage. However, the presence of adverse factors (AF) and advanced stages decrease the efficacy of this therapy: 5-year progression-free survival (PFS) and overall survival (OS) are about 50%. Due to the rarity PIAL the optimal treatment strategy for this patients (pts) remains unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Evgeniy Zvonkov, Nelli Gabeeva, Anna Sidorova, Anna Morozova, Olga Gavrilina, Hunan Julhakyan, Darya Koroleva, Alla Kovrigina, Tatyana Obukhova, Elena Parovichnikova, Valeriy Savchenko Source Type: research

Targeting mTOR/PI3K in Primary CNS Lymphoma (PCNSL)
The prognosis of PCNSL remains worse than that of other diffuse-large B-cell lymphomas. Thus, there is a big need for further therapeutic improvement. Dysregulation of various cellular pathways, such as NFkB, toll-like receptor or B-cell receptor signaling have been reported in PCNSL and constitute a potential therapeutic target. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Agnieszka Korfel, Elisabeth Schorb, Uwe Schlegel, Sa ša Dimitrijević Dimitrijević, Saana D'Allonzo, Martin Dreyling, Ullrich Herrlinger, Philipp Kiewe Source Type: research

RELINFO - Brazilian Network for Lymphoma Registry in Rio de Janeiro: Preliminary Results
There are few data in the incidence, monitoring and prognosis of lymphomas patients in Brazil. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Leonardo Gomes, Adriana Scheliga, Marcio Hori, Monica Prexedes, Fernando Monteiro, Marilza Magalh ães, Rita Spariz, Kellen Blanco, Luciana Conti, Glaucia Guasti, Solange Elehep Source Type: research

Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma (MCL) Cells
MCL cells exhibit chronic-active BCR signaling and downstream pro-growth and pro-survival NFkB activity. Ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase (BTK) yields high overall response rate in relapsed/refractory MCL, but approximately 40% of patients demonstrate primary refractory/resistant disease. Mutations in CARD11/IKBKB/TRAF2/BIRC3/NIK or in B-cell receptor (BCR) signaling induce activity of the classical or alternative NFkB pathway, conferring resistance to ibrutinib in MCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kapil Bhalla, Baohua Sun, Warren Fiskus, Liang Zhang, Dyana Saenz, Christopher Mill, Michael Wang Source Type: research

Myc+ Single-Hit Lymphoma Patients had Benefit from Dose-Intensified Chemotherapy
B-cell lymphomas with c-MYC rearrangement characterized by aggressive clinical behavior and poor prognosis when R-CHOP-21 is used. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Anna Misyurina, Elena Baryakh, Sergey Kravchenko, Alla Kovrigina, Tatyana Obukhova, Vsevolod Misyurin, Jana Mangasarova, Lubov Plastinina, Ekaterina Nesterova, Aminat Magomedova, Ekaterina Penskaya, Hunan Julhakyan, Andrey Vorobiev Source Type: research

Chemotherapy of Primary Mediastinal B-Cell Lymphoma
Primary mediastinal B-cell lymphoma (PMBCL) amounts from 0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women. All relapses in PMBCL occur as early events. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL (2-year overall survival (OS) is about 15% [Kurvilla J., 2008]), it is necessary to achieve a complete remission (CR) in first line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jana Mangasarova, Aminat Magomedova, Ekaterina Nesterova, Hunan Julhakyan, Sergey Kravchenko Source Type: research

Anaplastic Large Cell Lymphoma in Adults: Results and New Approach of Treatment
Anaplastic Large Cell Lymphoma (ALCL) represents subgroupe of peripheral T-cell lymphoma and constitutes 10-12% of this group. According to WHO 2008 classification two types depending on presence of ALK gene rearrangement subdivide ALCL: ALK-positive (ALCL ALK+) and ALK-negative (ALCL ALK-). ALCL ALK+ has a favorable prognosis with CHOP in patients without adverse prognostic factors and event free survival (EFS) reaches 70-75%. ALCL ALK- has worse treatment results: when using CHOP overall survival (OS) and EFS does not reach more than 50%. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Liliia Gorenkova, Elizaveta Klebanova, Ekaterina Penskaya, Hunan Julhakyan, Sergey Kravchenko, Valeriy Savchenko Source Type: research

The High Efficiency of AutoSCT in the Treatment of Refractory Follicular Lymphoma (FL): Results of the First Russian Prospective Study
FL represents one of the most frequent type of lymphomas: about 22% of non-Hodgkin lymphomas in Russia. 20% of patients (pts) are refractory to conventional R-CHOP therapy with dismal outcome. In cases with progressive tumor on induction therapy, autoSCT allows to increase the overall (OS) and progression-free survival (PFS). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ekaterina Nesterova, Sergey Kravchenko, Jana Mangasarova, Vladimir Vorobyev, Eduard Gemdzhian, Hunan Julhakyan, Andrey Vorobyev, Valery Savchenko Source Type: research

Leukemization of Follicular Lymphoma: Diagnostic Features and Clinical Course of a Rare Form of the Disease
Follicular lymphoma is a frequent lymphoid neoplasm, accounting for 22 percent of all non-Hodgkin's lymphoma in Russia. At diagnosis, some patients with FL manifest a detectable leukemic phase – leukemization (FL-LP), but this feature has been seldom described and has a poor prognosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ekaterina Nesterova, Alla Kovrigina, Jana Mangasarova, Lybov Plastinina, Tatyana Obukhova, Eduard Gemdzhian, Hunan Julhakyan, Ivan Vorobyev, Sergey Kravchenko Source Type: research

Immune Cell Modulations in Nordic FL Patients After Lenalidomide in the SAKK 35/10 Trial
Follicular lymphoma (FL) is although responsive to various therapies considered incurable. Rituximab is known to have improved outcome, which seems to be accentuated if combined with lenalidomide. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sandra Lockmer, Åsa Jeppsson-Ahlberg, Birgitta Sander, Eva Kimby, Björn Wahlin Source Type: research

Insights on Treating HCV-Related B Cell Non-Hodgkin Lymphoma
The risk to develop B-cell Non-Hodgkin Lymphoma (B-NHL) increases in chronic Hepatits C (HCV), molecular mechanisms are poorly understood. The most common NHL subtypes in this setting are Marginal Zone Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL). In Brazil, we lack epidemiologic and clinical evidence in this scenario. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ana Pittella, Elias Atta, Leonardo Gomes, Clarissa Cavalin Silva, Ana Ang élica Pimenta Source Type: research

Epidemiology of Common Lymphoid Malignancies in the Veteran Health Administration
The Veterans Health Administration (VHA) is the largest integrated health care system in the US, with 1,700 clinics and 152 hospitals in 50 states serving up to 8.5 million Veterans per year. VHA electronic medical record (EMR) information is collected in a single corporate data warehouse (CDW). There has been little to no research into the epidemiology of common lymphoid malignancies in the VHA, or associated practice patterns and outcomes. We therefore piloted a study of the incidence of three common lymphoid malignancies in the VHA using EMR data. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ahmad Halwani, Zachary Burningham, Brian Sauer Source Type: research

Discordance Between the Prognostic Impact of MIPI and Overall Survival in a Multicenter Cohort of Patients with Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) has historically been associated with poor long-term outcomes in many patients (pts). The MCL International Prognostic Index (MIPI) has attempted to improve risk-stratification by dividing patients into three groups based on available clinical and laboratory data. We conducted a multicenter analysis of MCL pts with robust clinical data to characterize the outcomes across risk categories in a heterogeneous population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ashley Staton, I. Greenwell, Jeffrey Switchenko, Joseph Maly, Kristie Blum, Steven Parks, Alexey Danilov, Christopher Flowers, Jonathon Cohen Source Type: research

Allogeneic Hematopoietic Stem Cell Transplantation in Mantle Cell Lymphoma: a Single Institution Experience
Treatment outcomes for mantle cell lymphoma (MCL) have improved with highly active targeted therapies; nonetheless it remains incurable, especially in patients with poor prognostic features. While autologous hematopoietic stem cell transplant (autoHSCT) has an established role as front-line consolidation, the role of allogeneic HSCT (alloHSCT) in MCL is less clear. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jose Sandoval-Sus, Julio Chavez, Paola Parra, Celeste Bello, Paul Chervenick, Jeffrey Lancet, Lubomir Sokol, Eduardo Sotomayor, Frederick Locke, Mohamed Kharfan-Dabaja, Bijal Shah, Ernesto Ayala Source Type: research

The Impact of Early Transformation in Low-Grade Lymphomas Treated with Anthracycline Based Chemoimmunotherapy
Transformed lymphomas (TL) are an aggressive, heterogeneous disease entity that usually represents the final stage of low-grade non-Hodgkin's lymphoma (LG-NHL) progression. We investigated the impact of early transformation of TL in patients treated with anthracycline-based chemoimmunotherapy (R-CHOP). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Samantha Shams, Luis Ju árez Salcedo, Patrick Griffin, José Sandoval-Sus, Celeste Bello, Bijal Shah, Ernesto Ayala, Mohamed Kharfan-Dabaja, Paul Chervenick, Eduardo Sotomayor, Lubomir Sokol, Julio Chavez Source Type: research

A Single Institution Analysis of Patients with Dual Diagnosis of T-Cell Large Granular Lymphocytic Leukemia and either a Plasma Cell and/or a B-Cell Lymphoproliferative Disorder
T-cell large granular lymphocytic leukemia (T-LGLL) is a rare malignancy arising from aberrant proliferations of large granular lymphocytes of post-thymic T-cell lymphocytes in peripheral blood, bone marrow, and spleen. Concurrent T-LGLL with either a B-cell or a plasma cell lymphoproliferative disorder is rare. T-LGLL can arise before, after, or concurrently at the time of diagnosis of a lymphoproliferative disorder (LPD). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Magali Van den Bergh, Leidy Isenalumhe, Emilie Wang, Stephanie Holdener, Ling Zhang, Lubomir Sokol Source Type: research

The Simultaneous Blockade of mTOR and Nuclear Transporter Exportin-1 Induces Synergistic Antitumor Effect through Pro-Survival Metabolism in Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with poor prognosis, characterized by aberrant expression of growth-regulating and oncogenic effectors. Novel therapeutic approaches are warranted for improved anti-tumor activity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kazumasa Sekihara, Kaori Saitoh, Takashi Miida, Michael Andreeff, Marina Konopleva, Yoko Tabe Tags: Research Topics Source Type: research

RESULTS of High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Brain Tumors
Central nervous system (CNS) tumors are the second most common pediatric malignancies with an about 30% 5-year overall survival rate in high-risk group. We tried to assess the effectiveness of high-dose chemotherapy (HDCT) with autologous hematopoietic stem-cell transplantation (auto-HSCT) in this patient group. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Asmik Gevorgian, Elena Morozova, Ilya Kazantsev, Tatiana Iukhta, Svetlana Safonova, Yury Punanov, Ludmila Zubarovskaya, Olga Zheludkova, Boris Afanasyev Source Type: research

Impact of the GSTA1 Gene Polymorphism on Clinical Outcomes of HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myeloid Leukemia
The occurrence of complications following HSCT of leukemic patients is highly variable and dependent on a multitude of host, donor, and treatment factors. Identifying important genetic variables will allow for better prediction of HSCT-related outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Mostafaf Mohammed Saleh, Essam El Beih, Raafat Abdel-Fattah, Hosam Kamel, Alaa El Haddad, Omar Fahmy, Mohamed Samra, Gamal Fathy, Gamal Ebid, Eman Radwan, Azza Kamel Source Type: research

Altered Expression of IARS (isoleucyl-tRNA synthetase) Genes in Leukemia
Aminoacyl tRNA synthetase (ARS/ARS2) being housekeeping genes, over a long period no one considered that it could have connection to any disease. Alterations in the ARS/ARS2 genes that facilitate mRNA translation generate many diseases, including cancer. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sanga Mitra, Arpa Samadder, Sayantani Sinha, Amitava Sengupta, Jayprokas Chakrabarti Source Type: research

Overexpression of the Transcription Factor Yin Yang 1 in Non-Hodgkin Lymphoma is associated with Chemo-Immune Resistance
A subset of patients with B-NHL initially does not respond to chemo-immunotherapies or relapses and no longer responds to further treatments. Therefore, there is an urgent need to identify underlying resistance factors and develops new targeted therapies to revers resistance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Luca Falzone, Massimo Libra, Benjamin Bonavida Source Type: research

Routine CMV Surveillance in Autologous Hematopoietic Cell Transplantation Setting: is It Time for Rethink?
In autologous hematopoietic cell transplantation (AHCT) setting, routine CMV surveillance is not indicated except in high-risk situations like using T-cell depleted grafts or treatment with fludarabine, alemtuzumab and 2-chlorodeoxyadenosine. CMV prevalence in Turkey is almost 90%. We retrospectively analyzed CMV reactivation and infection rates in patients without any high-risk features, who were treated with AHCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ali Kaya, Emre Tekg ündüz, Seval Akpınar, Ömür Kayıkçı, Filiz Bekdemir, Bilge Ugur, Hikmetullah Batgi, Tugce Yigenoglu, Bahar UncuUlu, Mehmet Dal, Dicle İskender, Merih Kızıl, Fevzi Altuntas Source Type: research

Attitudes Towards Hematopoietic Stem Cell Transplantation (HSCT) - Differences Between Physicians and Nurses
Hematopoietic stem cell transplantation (HSCT) is a highly intensive medical procedure and the medical staff at a transplant unit experiences high levels of psychological distress. Since doctors and nurses differ in their clinical training, the level of professional indoctrination and in the duration and nature of exposure to the patients, we hypothesized that they hold different perspective towards the procedure. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Oren Pasvolsky, Uri Rozovski, Pia Raanani, Moshe Yeshurun Source Type: research

A Pharmacokinetic/Pharmacodynamic Perspective on the Effect of Bruton's Tyrosine Kinase Inhibitors on Collagen-Induced Platelet Aggregation
Bruton's tyrosine kinase (BTK) and TEC may perform redundant functions in collagen-induced platelet (PLT) aggregation. Ibrutinib (ibr), a first-in-class, once-daily inhibitor of BTK, is indicated for the treatment of patients with B-cell malignancies and allows for treatment without chemotherapy. Clinical trials on ibr and other BTK inhibitors (BTKis), including ONO-4059 and ACP-196, identified bleeding as an adverse event, but whether bleeding is from inhibition of BTK or both BTK and TEC remains unclear. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jun Chen, Taisei Kinoshita, Tarikere Gururaja, Juthamas Sukbuntherng, Danelle James, Matthias Versele, Betty Chang Source Type: research

Myelotoxicity and Reduction in Number of CD34 + Early Hematopoietic Progenitors in Adult Poor-Prognosis Patients with Diffuse Large B-Cell Lymphoma in Late Period After High-Dose Chemotherapy by mNHL-BFM-90
Myelopoiesis recovery after high-dose chemotherapy by mNHL-BFM-90 in adult patients with DLBCL is not studied, but it is important to assess the quality of life and in the case of relapse and subsequent chemotherapy (CT). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Elena Dorokhina, Aminat Magomedova, Irina Galtseva, Valentina Dvirnyk, Svetlana Glinkina, Sergey Kulikov, Tatyana Obukhova, Hunan Julhakyan, Sergey Kravchenko Source Type: research

IgVH Genes Somatic Mutations in Splenic Marginal Zone Lymphoma
Splenic marginal zone lymphoma (SMZL) is a disease with an indolent clinical course and the precise prognostic significance of IGVH genes mutation is not clear yet. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Hunan Julhakyan, Bella Biderman, Igor Yakutik, Lyubov Al-Radi, Tatyana Moiseeva, Anait Melikyan, Elena Gribanova, Eduard Gemdzhian, Andrey Sudarikov, Valeriy Savchenko Source Type: research

Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: a Single-Center Study at the American University of Beirut Medical Center (AUBMC)
Cytomegalovirus reactivation (R-CMV) is often diagnosed in allogeneic hematopoietic cell transplant recipients and could determine a CMV-related disease in these immunocompromised patients, involving any organ. R-CMV and end-organ disease after ASCT has not been studied thoroughly. Autograft recipients are generally considered to have low risk of R-CMV or end-organ disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Radwan Massoud, Rita Assi, Elie Fares, Nabila Kreidieh, Rami Mahfouz, Souha Kanj-Sharara, Aline El-Zakhem, Mohamed Kharfan-Dabaja, Ali Bazarbachi, Jean El Cheikh Source Type: research

Cyclosporine (CsA) Pharmacogenetics Post HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myeloid Leukemia: Value of CYP3A4 Gene Polymorphism
Variant genotypes of CYP3A4 gene polymorphism (A290G) is associated with decreased enzymatic activity that could interfere with CsA metabolism post HSCT in leukemic patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Essam El-Beih, Raafat Abdel Fattah, Mohammed Samra, Hosam Kamel, Alaa El Haddad, Oma Fahmy, Gamal Ebid, Gamal Fathy, Eman Radwan, Azza Kamel Source Type: research

Phenotypic Profile of Rh and Kell Blood Group Systems in Blood Donors and Patients with Hematologic Malignancies: a Report from Armenia
In order to prevent post-transfusion reactions in patients with hematologic malignancies receiving blood transfusions, careful assessment of RBC antigens is of a great importance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Izabella Azizyan, Samvel Danielyan, Liana Avetisyan, Nune Gevorgyan, Armen Avagyan, Lusine Hakobyan, Samvel Iskanyan, Astghik Voskanyan, Davit Zohrabyan, Liana Safaryan, Lilit Harutyunyan, Samvel Bardakchyan, Sergey Mkhitaryan, Nelly Musaelyan, Suren Amir Source Type: research

Risk Factors for Graft-Versus-Host Disease after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide
Risk factors for graft-versus-host disease (GVHD) development after nonmyeloablative (NMA) human leukocyte antigen (HLA)-haploidentical (haplo) BMT with posttransplantation cyclophosphamide (PTCy) are unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Shannon McCurdy, Christopher Kanakry, Yvette Kasamon, Hua-Ling Tsai, Margaret Showel, Javier Bolanos-Meade, Jennifer Kanakry, Heather Symons, Ivana Gojo, B. Douglas Smith, Maria Bettinotti, Ephraim Fuchs, Gary Rosner, Rick Jones Source Type: research

Chemotherapy Induced Thrombocytopenia in Children and Young Adults with Hematologic Malignancies
Thrombocytopenia is one of the most common complications of chemotherapy of hematologic malignancies, but the data is limited in children and young adults. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sergey Mkhitaryan, Samvel Bardakchyan, Samvel Danielyan, Armen Avagyan, Lilit Sargsyan, Lusine Hakobyan, Samvel Iskanyan, Astghik Voskanyan, Davit Zohrabyan, Liana Safaryan, Lilit Harutyunyan, Gevorg Tamamyan Source Type: research

Anemic Use of Publication Bias Assessments in Hematology Systematic Reviews: a Chronic Disease
Publication bias (PB) is an over-representation of statistically significant results in the published literature and may exaggerate summary effect estimates in hematology systematic reviews (SRs). Omitting non-significant results in SRs may therefore affect clinical decision making. We investigate ways that systematic reviewers in hematology attempted to limit PB during the search process as well as the statistical methods used to evaluate it. For a subset of reviews not reporting PB evaluations, we performed our own assessments for PB to determine its likelihood among these reviews. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Cole Wayant, Caleb Smith, Matt Vassar Source Type: research

Hematology Journals Make Poor Use of Reporting Guidelines: 40% Percent Require None at All
The objective of this study was to investigate the policies of Hematology journals concerning reporting guideline adoption and clinical trial registration to understand the extent to which journals are using these mechanisms as a means to improve study quality and reporting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Cole Wayant, Caleb Smith, Matthew Sims, Matt Vassar Source Type: research

Single-Cell RNA-Seq Allows Deep Analysis of the Tumor Immune Microenvironment and Alterations Induced by Anti-PD-1 Treatment
Despite the impressive clinical results seen with immune checkpoint inhibitors, we have only a limited understanding of the immunologic changes within the tumor microenvironment that result from checkpoint blockade. A deeper understanding of the treatment effects on the microenvironment is required to predict which patients will respond, develop adjuvant agents to increase response rates, and discover the next generation of immune modulating therapies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Brian Miller, Marc Wadsworth, Kevin Bi, Travis Hughes, Arlene Sharpe, Alex Shalek, W. Haining Source Type: research

Targeting Innate and Adaptive Immune Responses for the Treatment of Acute Myeloid Leukemia
Successful immunotherapeutic approaches for acute myeloid leukemia (AML) have yet to be developed. We hypothesized that targeting both the innate and adaptive immune responses in leukemic hosts would elicit significant anti-tumor activity with lesser toxicities than chemotherapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Amanda Przespolewski, Scott Portwood, Jason Den Haese, Eunice Wang Source Type: research

Hereditary Hematologic Malignancies: Genetic Counseling Implementation in a Large Leukemia Center
Hematologic malignancies have rarely been targets for genetic evaluation, even in familial cases. Over the past decade,>12 genes have been identified to cause inherited predispositions to hematologic malignancies. Genetic counseling, testing, and surveillance protocols for these families are not well-established. Many families with high incidence of blood cancers do not have described syndromes suggesting additional genes remain to be identified. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sarah Bannon, Courtney DiNardo Source Type: research

Anemic Outcome Reporting Consistency: Evidence of Selective Reporting Bias in Leading Hematology Journals
Selective outcome reporting is a significant methodological concern leading to potential bias in clinical trial results. Comparisons between outcomes reported in trial registries and journal publications allow investigators to examine the frequency of selective reporting occurrences among trialists. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Cole Wayant, Caleb Scheckel, Chandler Hicks, Tim Nissen, Linda Leduc, Mousumi Som, Matt Vassar Source Type: research

Determining Treatment for Older Patients with High-Risk MDS and AML: which Factors Predict Optimal Quality of Life?
Evidence is lacking to guide patients diagnosed with acute myeloid leukemia and high-risk myelodysplastic syndrome in selecting the best treatment for improving quality of life. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sara Tinsley, Brent Small, Susan McMillan, Rami Komrokji, Jeffrey Lancet Source Type: research

Editorial Board/Masthead
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Source Type: research